Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Study sponsor: Boehringer Ingelheim

To Learn More Contact
Boehringer Ingelheim Call Center at1-800-243-0127 orĀ  clintriage.rdg@boehringer-ingelheim.com
ClinicalTrials.gov identifier: NCT02770170

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up